Page 19 - PD-L1 EbookV2 Flip PDF

Figure 2. Relative dollar impact of each optimized driver.

Using the model to determine the relative percentage impact of each optimized driver
(cumulative five year revenues) showed that having all drivers optimized would confer an
additional eight per cent of revenue over the single drivers alone.

Another way to consider this is as year on year lost treatment revenue. The model suggests
that therapies have already lost around $40 million in treatment opportunity due to
suboptimal testing. This accumulates over five years to $744 million in lost therapy
opportunity in second line NSCLC alone, otherwise achieved if all drivers had been
optimized (Figure 3).

Finally, when looking at the ROI of diagnostic driver investments expressed in anti PD-1
therapy dollars we saw that investment in greater test accuracy delivers the single greatest
dollar for dollar return, but having all drivers optimized provides $24 for every $1 invested in
diagnostics for this indication.

Figure 3. Lost treatment opportunity in second line NSCLC ($m).

Page 19 of 31